Presentation is loading. Please wait.

Presentation is loading. Please wait.

American Heart Journal

Published byEthelbert Clark Modified over 6 years ago

Similar presentations

Presentation on theme: "American Heart Journal"— Presentation transcript:

1 American Heart Journal
Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project  Paul L. Hess, MD, MHS, Kevin Kennedy, MS, Michael Cowherd, MD, Salim S. Virani, MD, PhD, Frederick A. Masoudi, MD, MSPH, Ann Marie Navar, MD, PhD, Robert W. Yeh, MD, MSc, P. Michael Ho, MD, PhD, Thomas M. Maddox, MD, MSc  American Heart Journal  DOI: /j.ahj Copyright © Terms and Conditions

2 Figure Proportion of patients with ASCVD potentially eligible for PCSK9 inhibitor therapy according to LDL-C treatment thresholds and statin intensity. American Heart Journal DOI: ( /j.ahj ) Copyright © Terms and Conditions

Download ppt "American Heart Journal"

Similar presentations

Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—A revisit.

Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—A revisit.
Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.
Routine invasive management early after fibrinolysis: Relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7.

Routine invasive management early after fibrinolysis: Relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7.
Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E
Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO 

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO 
Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population  Richard K. Cheng, MD, MS,

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population  Richard K. Cheng, MD, MS,
Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.

Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.
Automatic Optimization of Cardiac Resynchronization Therapy Using SonR—Rationale and Design of the Clinical Trial of the SonRtip Lead and Automatic AV-VV.

Automatic Optimization of Cardiac Resynchronization Therapy Using SonR—Rationale and Design of the Clinical Trial of the SonRtip Lead and Automatic AV-VV.
Total arterial revascularization of triple vessel coronary disease based on combined internal thoracic and radial artery grafts  Robert H. Habib, PhD,

Total arterial revascularization of triple vessel coronary disease based on combined internal thoracic and radial artery grafts  Robert H. Habib, PhD,
Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: An analysis from the Blue Cross Blue Shield of Michigan.

Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: An analysis from the Blue Cross Blue Shield of Michigan.
Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice  Manesh R.

Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice  Manesh R.
Robert Roberts, MD, FRCPC, MACC  Canadian Journal of Cardiology 

Robert Roberts, MD, FRCPC, MACC  Canadian Journal of Cardiology 
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Manuel J. Antunes, MD, PhD, DSc 

Manuel J. Antunes, MD, PhD, DSc 
National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance  Judith.

National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance  Judith.
Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.
Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: The.

Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: The.
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)  Emily C. O’Brien, PhD,

Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)  Emily C. O’Brien, PhD,
The Demise of Morphine Oxygen Nitroglycerin Aspirin (MONA)

The Demise of Morphine Oxygen Nitroglycerin Aspirin (MONA)

Similar presentations

Ads by Google